Abstract
Most diseases that cause blindness do so as a result of neovascularization. Angiogenesis is a complex process regulated in adult tissues by a large interacting network of molecules. In pathological conditions the checks and balances of the angiogenesis system go awry and endothelial cells of the microvasculature, proliferate, migrate, and form new but leaky vessels that invade the tissue. Hemorrhaging vessels cause edema and damage to surrounding tissues, particularly the retina. Microvascular lesions often cause severe retinal detachment and loss of vision. In this review, the value of an important endogenous anti angiogenic molecule, PEDF, is discussed in relationship to its ability to prevent retinal cell death and counter the abnormal vessel growth induced by VEGF in the eye. Its control of a neuroprotective and an antineovascular regulatory axis that determines cell fate, and its possible use in combination therapeutic strategies for ocular neovascular diseases are also reviewed.
Keywords: Angiogenesis, pigment epithelial derived factor, vascular endothelial derived factor, age related macular degeneration, diabetic retinopathy, microvascular lesions, retina
Current Molecular Medicine
Title: PEDF in Angiogenic Eye Diseases
Volume: 10 Issue: 3
Author(s): J. Tombran-Tink
Affiliation:
Keywords: Angiogenesis, pigment epithelial derived factor, vascular endothelial derived factor, age related macular degeneration, diabetic retinopathy, microvascular lesions, retina
Abstract: Most diseases that cause blindness do so as a result of neovascularization. Angiogenesis is a complex process regulated in adult tissues by a large interacting network of molecules. In pathological conditions the checks and balances of the angiogenesis system go awry and endothelial cells of the microvasculature, proliferate, migrate, and form new but leaky vessels that invade the tissue. Hemorrhaging vessels cause edema and damage to surrounding tissues, particularly the retina. Microvascular lesions often cause severe retinal detachment and loss of vision. In this review, the value of an important endogenous anti angiogenic molecule, PEDF, is discussed in relationship to its ability to prevent retinal cell death and counter the abnormal vessel growth induced by VEGF in the eye. Its control of a neuroprotective and an antineovascular regulatory axis that determines cell fate, and its possible use in combination therapeutic strategies for ocular neovascular diseases are also reviewed.
Export Options
About this article
Cite this article as:
Tombran-Tink J., PEDF in Angiogenic Eye Diseases, Current Molecular Medicine 2010; 10 (3) . https://dx.doi.org/10.2174/156652410791065336
DOI https://dx.doi.org/10.2174/156652410791065336 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Polymeric Nanoparticles for Ophthalmic Drug Delivery: An Update on Research and Patenting Activity
Recent Patents on Nanomedicine MDMA Toxicity and Pathological Consequences: A Review About Experimental Data and Autopsy Findings
Current Pharmaceutical Biotechnology Neuronal and Glial Cell Abnormality as Predictors of Progression of Diabetic Retinopathy
Current Pharmaceutical Design Effect of Intravitreal Injection of Aflibercept on Cardiovascular Risk Parameters in Patients with Neovascular Age-Related Macular Degeneration
Current Reviews in Clinical and Experimental Pharmacology Central Retinal Vein Occlusion: Current Therapeutic Approach
Vascular Disease Prevention (Discontinued) Intravitreal Anti-VEGF Drugs as Adjuvant Therapy in Diabetic Retinopathy Surgery
Current Diabetes Reviews Polyphenols and Neuroprotection against Ischemia and Neurodegeneration
Mini-Reviews in Medicinal Chemistry Regulation of Angiogenesis by Macrophages, Dendritic Cells, and Circulating Myelomonocytic Cells
Current Pharmaceutical Design Pathophysiology of Blood-Spinal Cord Barrier in Traumatic Injury and Repair
Current Pharmaceutical Design Vasoactive Factors and Diabetic Retinopathy: Vascular Endothelial Growth Factor, Cycoloxygenase-2 and Nitric Oxide
Current Pharmaceutical Design Angiogenesis as Risk Factor for Plaque Vulnerability
Current Pharmaceutical Design Targeting Heme Oxygenase-1 in Vascular Disease
Current Drug Targets Regulation of Angiogenesis and Angiogenic Factors by Cardiovascular Medications
Current Pharmaceutical Design Intravitreal Steroids for the Prevention of PVR After Surgery for Retinal Detachment
Current Pharmaceutical Design The State-of-Art in Angiogenic Properties of Latex from Different Plant Species
Current Angiogenesis (Discontinued) Anti-VEGF Treatment in Corneal Diseases
Current Drug Targets Ocular Complications of Drugs Used in Rheumatic Disease
Current Rheumatology Reviews Role of Endothelin in Diabetic Retinopathy
Current Vascular Pharmacology Advanced Drug Delivery of N-Acetylcarnosine (N-Acetyl-beta-alanyl-Lhistidine), Carcinine (Beta-alanylhistamine) and L-carnosine (Beta-alanyl- L-histidine) in Targeting Peptide Compounds as Pharmacological Chaperones for Use in Tissue Engineering, Human Disease Management and Therapy: From in vitro to the Clinic
Recent Patents on Drug Delivery & Formulation Management of Idiopathic Intracranial Hypertension During the COVID-19 Pandemic
Reviews on Recent Clinical Trials